BIO Announces Initial Selection of Life Sciences Companies to ...

seedextralargeBiotechnology

Dec 1, 2012 (4 years and 7 months ago)

182 views

“The companies making
presentations at this
year’s BIO CEO &
Investor Conference
bring with them a broad
range of innovative new
therapies in the life
sciences sector”
December 13, 2010 11:11 AM Eastern Time
BIO Announces Initial Selection of Life Sciences Companies to Present at the 13th Annual BIO
CEO & Investor Conference
An International Biotechnology Investor Conference Featuring Established & Emerging Public Companies
BIO CEO & Investor Conference 2011
WASHINGTON--(
BUSINESS WIRE
)--The
Biotechnology Industry Organization
(BIO) today announced the initial selection of
presenting companies for the
13
th
Annual BIO CEO & Investor Conference
, taking place at the Waldorf=Astoria Hotel in New
York City on February 14-15, 2011.
“The companies making presentations at this year’s BIO CEO & Investor Conference bring with
them a broad range of innovative new therapies in the life sciences sector,” said Alan
Eisenberg, executive vice president, Emerging Companies & Business Development at BIO.
“This is an ideal venue for investors, analysts, and executives alike to get the pulse on the
current and proposed investment trends in biotechnology.”
BIO and the conference advisory committee established the criteria for presenting companies.
The advisory committee is comprised of members from top-tier firms focused on investing and
banking in the life sciences industry in addition to executives from emerging and leading
biotech companies. Following are the members of the 13
th
Annual BIO CEO & Investor
Conference Advisory Committee:
Hany Awadalla, Managing Director, Rodman & Renshaw, LLC.
Ron Cohen, MD President & Chief Executive Officer, Acorda Therapeutics
John Crowley, President & Chief Executive Officer, Amicus Therapeutics
J. Donald deBethizy, PhD, President & Chief Executive Officer, Targacept, Inc.
David Farhadi, MD, Vice President & Portfolio Manager, Fred Alger Management
Annette Grimaldi, Managing Director, BMO Capital Markets
Rajiv Kaul, Portfolio Manager/Research Analyst, Fidelity Investments
Thomas Okarma, President & Chief Executive Officer, Geron Corporation
Stephen Sands, Vice Chairman, US Investment Banking; Co-Head of Global Healthcare Group, Lazard
Chris Swindle, Managing Director, Wedbush PacGrow Life Sciences
Yaron Werber, MD, Director & Senior Biotechnology Analyst, Citi Investment Research
The BIO CEO & Investor Conference will feature presentations from more than 130 emerging and established public biotech
companies and non-profit funding organizations.
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 1/6
The following companies will present at the 13
th
Annual BIO CEO & Investor Conference:
Aastrom Biosciences, Inc.:
ASTM
ACADIA Pharmaceuticals Inc.:
ACAD
Acorda Therapeutics, Inc.:
ACOR
Addex Pharmaceuticals:
SWF:ADXN
Advanced Cell Technology, Inc.:
ACTC
ADVENTRX Pharmaceuticals, Inc.:
AMEX:ANX
Aegerion Pharmaceuticals, Inc.:
AEGR
Aeolus Pharmaceuticals, Inc.:
OTC:AOLS
Affymax, Inc.:
AFFY
Agennix AG:
ETR:AGX
Alimera Sciences, Inc.:
ALIM
Alkermes, Inc.:
ALKS
Allon Therapeutics Inc.:
TSE:NPC
Alnylam Pharmaceuticals, Inc.:
ALNY
Amsterdam Molecular Therapeutics:
AMS:AMT
Apricus Biosciences, Inc.:
APRI
Aradigm Corporation:
OTC:ARDM
Arena Pharmaceuticals, Inc.:
ARNA
ARIAD Pharmaceuticals, Inc.:
ARIA
AVI BioPharma, Inc.:
AVII
BioDelivery Sciences International:
BDSI
BioSante Pharmaceuticals, Inc.:
BPAX
Cadence Pharmaceuticals, Inc.:
CADX
CEL-SCI Corporation:
CVM
Cempra Pharmaceuticals: Private
Cerus Corporation:
CERS
ChemGenex Pharmaceuticals:
ASX:CXS
Cleveland BioLabs Inc.:
CBLI
Clinical Data, Inc.:
CLDA
CorMedix Inc.:
CRMD
Curis Inc.:
CRIS
Cyclacel Pharmaceuticals, Inc.:
CYCC
Cytokinetics, Inc.:
CYTK
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 2/6
Cytos Biotechnology AG:
SWF:CYTN
CytRx Corporation:
CYTR
Depomed, Inc.:
DEPO
DURECT Corporation:
DRRX
Elite Pharmaceuticals, Inc.:
OTC:ELTP
EpiCept Corporation:
EPCT
Exelixis, Inc.:
EXEL
Furiex Pharmaceuticals, Inc.:
FURX
Genta Incorporated:
OTC:GETA
GenVec, Inc.:
GNVC
Geron Corporation:
GERN
GlobeImmune Inc.: Private
Hybrigenics S.A.:
EPA:ALHYG
Icagen, Inc.:
ICGN
Idenix Pharmaceuticals, Inc.:
IDIX
Idera Pharmaceuticals, Inc.:
IDRA
ImmunoGen, Inc.:
IMGN
Immunovaccine Inc.:
CVE:IMV
Inovio Pharmaceuticals, Inc.:
AMEX:INO
Karo Bio AB:
STO:KARO
Keryx Biopharmaceuticals, Inc.:
KERX
Lexicon Pharmaceuticals, Inc.:
LXRX
Ligand Pharmaceuticals, Inc.:
LGND
Medicago Inc.:
CVE:MDG
MethylGene Inc.:
TSE:MYG
Momenta Pharmaceuticals, Inc.:
MNTA
Myriad Genetics, Inc.:
MYGN
Neoprobe Corporation:
OTC:NEOP
NeurogesX, Inc.;
NGSX
Novavax, Inc.:
NVAX
Oncolytics Biotech Inc.:
TSE:ONC
Oncothyreon Inc.:
ONTY
Opexa Therapeutics, Inc.:
OPXA
OXiGENE, Inc.:
OXGN
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 3/6
PDL BioPharma, Inc.:
PDLI
Peregrine Pharmaceuticals, Inc.:
PPHM
PolyMedix Inc.:
OTC:PYMX
Pro-Pharmaceuticals, Inc.:
PRWP
PTC Therapeutics, Inc.: Private
QRxPharma Limited:
ASX:QRX
RegeneRx Biopharmaceuticals, Inc.:
RGN
Repligen Corporation:
RGEN
Resverlogix Corp.:
TSE:RVX
Rigel Pharmaceuticals, Inc.:
RIGL
Sangamo BioSciences, Inc.:
SGMO
Santarus, Inc.:
SNTS
SciClone Pharmaceuticals, Inc.:
SCLN
SIGA Technologies, Inc.:
SIGA
Soligenix, Inc.:
OTC:SNGX
Somaxon Pharmaceuticals:
SOMX
Spectrum Pharmaceuticals, Inc.:
SPPI
Sunesis Pharmaceuticals, Inc.:
SNSS
SuperGen, Inc.:
SUPG
Synergy Pharmaceuticals, Inc.:
OTC:SGYP
Synta Pharmaceuticals Corp.:
SNTA
Targacept, Inc.:
TRGT
Tekmira Pharmaceuticals Corporation:
TSE:TKM
Telik, Inc.:
TELK
Tengion, Inc.:
TNGN
Topotarget A/S:
CPH:TOPO
Transcept Pharmaceuticals, Inc.:
TSPT
Unigene Laboratories, Inc.:
OTC:UGNE
VirtualScopics:
VSCP
XOMA LLC:
XOMA
YM BioSciences Inc.:
TSE:YM
Zalicus Inc.:
ZLCS
ZIOPHARM Oncology, Inc.:
ZIOP
The program will also include therapeutic workshops featuring CSOs, MDs and industry analysts discussing new therapies and
the latest areas of pipeline innovation in rheumatology, hepatology, endocrinology, neurology, and oncology.
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 4/6
Business Roundtables will focus on current investment trends and topics in biotechnology including financing, business
development, licensing, M&A, clinical trial success rates, and reimbursement strategies. In addition, plenary session topics will
highlight investor perceptions of the industry and the health policy outlook for 2011.
Attendees will have the opportunity to network with leading industry executives and investors, as well as utilize the BIO One-on-
One Partnering system to set up investment meetings with new and existing contacts.
Additional presenting companies are confirmed each day. For the most up-to-date list, please visit
http://bio.org/bioceo
.
Registration is complimentary for qualified investors and members of the media.
About the 13
th
Annual BIO CEO & Investor Conference
The BIO CEO & Investor Conference is a must attend event for institutional investors, industry analysts, and senior biotechnology
executives focused on shaping the future investment landscape of the biotechnology industry.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors, including Lead Bank
Sponsor Wedbush PacGrow Life Sciences, Host Bank Sponsor Rodman & Renshaw LLC, and Supporting Bank Sponsors BMO
Capital Markets, Deutsche Bank, and Lazard.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related
organizations across the United States and in more than 30 other nations. BIO members are involved in the research and
development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the
BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIO produces
BIOtech Now
, an online portal and monthly newsletter chronicling
“innovations transforming our world.”
Subscribe to BIOtech Now.
Upcoming BIO Events
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
December 11-14, 2010
Honolulu, HI
BIO Asia International Partnering Conference
January 24-25, 2011
Tokyo, Japan
BIO CEO & Investor Conference
February 14-15, 2011
New York, NY
BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy
BIO Intellectual Property Counsels Committee Spring Conference and Committee Meeting
April 13-15, 2011
Seattle, WA
BIO International Convention
June 27-30, 2011
Washington, DC
Contacts
Biotechnology Industry Organization (BIO)
Erin Reese, 202-962-9235
www.bio.org
Permalink: http://www.businesswire.com/news/home/20101213006174/en/BIO-Announces-Initial-Selection-Life-Sciences-Companies
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 5/6
06/01/2011 BIO Announces Initial Selection of Lif…businesswire.com/…/BIO-Announces-I… 6/6